Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong revenue growth, record high gross margins, and improved EBITDA, indicating operational efficiency. Positive sentiments arise from planned AI-driven product enhancements and international expansion. Although Q1 guidance is lower due to seasonality, the full-year outlook remains robust. The Q&A session reveals optimism in subscription growth and international expansion, despite management's reluctance to provide specific churn metrics. Given these factors, the stock price is likely to experience a positive movement, driven by strong financial performance and strategic growth initiatives.
Q4 2025 Revenue $26.6 million, increasing 29.6% year-over-year. Revenue strength was driven by broad-based growth across the Dream product suite and Owlet360 subscription.
Full Year 2025 Revenue $105.7 million, a 35.4% growth over 2024. Growth attributed to strong performance across product lines and subscription services.
Q4 2025 Gross Margin 47.6%, including a 510 basis point impact from the cost of tariffs.
Full Year 2025 Gross Margin 50.6%, a record high, despite a 270 basis point impact from tariff costs.
Q4 2025 Adjusted EBITDA $0.1 million compared to $0.5 million in Q4 2024. Tariff costs were the primary impact versus prior year's adjusted EBITDA.
Full Year 2025 Adjusted EBITDA $2 million, a $3.8 million improvement over 2024, showcasing operational efficiency.
International Revenue Q4 2025 $3.9 million, with a record year total of $19.2 million, up 27% versus 2024. Decline in Q4 attributed to transitioning Amazon U.K. to a direct import model.
Operating Expenses Q4 2025 $17.5 million, improving by $0.9 million compared to Q4 2024. As a percentage of revenue, operating expenses were 66% compared to 90% in Q4 2024.
Net Loss Q4 2025 $9.2 million versus $9.1 million in Q4 2024.
Cash and Cash Equivalents Q4 2025 $35.5 million, up from $23.8 million in Q3 2025. Increase due to proceeds from the equity offering in October.
Owlet360 Subscription Service: Launched in January 2025, it has over 110,000 paying subscribers as of March 2025. Expanded internationally to countries like the UK, Ireland, Australia, New Zealand, and South Africa.
Dream Sight Camera: Launched in September 2025, it features onboard AI capabilities and integrates with Dream Sock for a comprehensive child wellness view. New camera-specific subscription features are planned for 2026.
Market Share in Baby Monitors: Owlet captured 41% of the baby monitor market in Q4 2025, a 24% increase from Q4 2024.
International Expansion: Revenue from international markets reached $19.2 million in 2025, with regulatory clearances for Dream Sock in India and Israel, targeting launches in 2026.
Revenue Growth: Achieved $105.7 million in revenue for 2025, a 35.4% increase from 2024.
Gross Margins: Full-year gross margins reached a record 50.6% despite tariff impacts.
Adjusted EBITDA: Recorded $2 million in adjusted EBITDA for 2025, a $3.8 million improvement over 2024.
Telehealth Platform (Owlet OnCall): Planned launch in 2026 to integrate real-time infant data for enhanced pediatric telehealth services.
Healthcare Channel Expansion: Expanded Medicaid reimbursement to 37 states and commercial insurance carriers to 258, covering over 90% of U.S. births.
Tariff Costs: Tariff costs have significantly impacted gross margins, reducing them by 510 basis points in Q4 2025 and 270 basis points for the full year. This remains a persistent challenge for the company.
Seasonality of Revenue: The business experiences significant seasonality, with Q1 consistently being the lowest revenue quarter. This could lead to cash flow challenges and operational inefficiencies during the first quarter of each year.
Economic and Geopolitical Uncertainty: The company faces risks from volatile tariff situations and the ongoing war in the Middle East, which could impact costs and supply chain stability.
Regulatory Approvals and Market Entry: While the company has made progress in securing regulatory approvals in new markets like India and Israel, delays or challenges in obtaining these approvals could hinder international expansion plans.
R&D Investment Costs: Increased investment in R&D for software and services, particularly for Owlet360 and OnCall Telehealth, could strain financial resources if these initiatives do not yield expected returns.
Healthcare Channel Expansion: The company is in the early stages of expanding its healthcare channels and hospital partnerships. Delays or challenges in these partnerships could impact growth in this strategic area.
Subscription Growth Dependency: The company’s growth strategy heavily relies on increasing subscription adoption. Failure to achieve expected subscription growth could impact long-term revenue and profitability.
Revenue Expectations for 2026: Owlet expects revenue in the range of $126 million to $130 million for 2026, representing growth of 19% to 23% over 2025. Revenue contribution is expected to be roughly 40% in the first half of 2026 and 60% in the back half due to seasonality and increasing subscription revenue.
Gross Margin Projections for 2026: Gross margins are expected to be in the range of 49% to 52% for the full year 2026, with tariff cost impacts consistent with Q4 2025 at 510 basis points to margin per quarter.
Adjusted EBITDA for 2026: Adjusted EBITDA is projected to be in the range of $3 million to $5 million, representing growth of 50% to 150% over 2025.
Q1 2026 Financial Outlook: Revenue is expected to be in the range of $20 million to $21 million, gross margins of 50% to 52%, and adjusted EBITDA of negative $2.5 million to negative $1.5 million. Q1 is expected to be the lowest revenue contribution quarter due to seasonality.
International Expansion: Owlet plans to launch Dream Sock in India and Israel in 2026, with India expected to launch in the first half and Israel in the back half of the year. These markets represent significant growth opportunities, with India having over 23 million annual births.
Owlet OnCall Telehealth Platform: The telehealth platform is expected to launch in the latter half of 2026, leveraging real-time infant data to enhance care quality and patient outcomes. The first half of 2026 will focus on testing and refining the platform.
Subscription Growth: Owlet plans to expand the Owlet360 subscription platform to additional regulatory-cleared countries in 2026, aiming to increase subscriber growth and customer lifetime value by integrating AI and camera-based features.
The selected topic was not discussed during the call.
The earnings call indicates strong financial performance with a 14.3% increase in FFO, reduced leverage, and strategic acquisitions. Management's focus on expanding in key markets and maintaining stable leasing spreads adds to the positive outlook. Although some responses were vague, the overall sentiment and financial metrics suggest a positive impact on stock price.
The earnings call highlights strong revenue growth, record high gross margins, and improved EBITDA, indicating operational efficiency. Positive sentiments arise from planned AI-driven product enhancements and international expansion. Although Q1 guidance is lower due to seasonality, the full-year outlook remains robust. The Q&A session reveals optimism in subscription growth and international expansion, despite management's reluctance to provide specific churn metrics. Given these factors, the stock price is likely to experience a positive movement, driven by strong financial performance and strategic growth initiatives.
The earnings call highlights strong financial performance with record revenue and profit, despite tariff challenges. Positive guidance and strategic initiatives, such as international expansion and healthcare partnerships, bolster growth prospects. The Q&A reveals confidence in ongoing partnerships and market expansion, though some details, like subscriber retention, remain vague. Overall, the strong earnings and optimistic guidance, coupled with strategic partnerships, suggest a positive stock price movement.
The earnings call presents mixed signals. Positive aspects include strong revenue growth, improved gross margins, and ongoing international expansion. However, the significant net loss due to a noncash adjustment, decreased international revenue, and tariff impacts are concerning. The Q&A highlighted slow healthcare progress and tariff challenges, but also potential growth in telehealth and hospital interest. The mixed financial performance, combined with the market's likely focus on the net loss and tariff impacts, suggests a neutral stock price reaction in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.